Bile acid transporters and regulatory nuclear receptors in the liver and beyond

Journal of Hepatology

Volumn 58, Issue 1, 2013, Pages 155-168

  Halilbasic, Emina ^a   Claudel, Thierry ^a   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bile acids; Cholestasis; Fatty liver disease; Gallstones; Liver cancer; Liver regeneration

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER B4; ANGIOTENSIN RECEPTOR ANTAGONIST; BICARBONATE; BILE ACID; BILE ACID TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CELL NUCLEUS RECEPTOR; CHOLESTEROL; DIGOXIN; DOXORUBICIN; FEXOFENADINE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INT 767; LEVOFLOXACIN; METHOTREXATE; MORPHINE 3 GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; OUABAIN; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHOLIPID; PREGNANE X RECEPTOR; PROTEIN TYROSINE PHOSPHATASE SHP; RETINOID X RECEPTOR; RIFAMPICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR;

APOPTOSIS; BASOLATERAL MEMBRANE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILE DUCT; CANCER RISK; CELL MEMBRANE; CELL PROTECTION; CHEMICAL MODIFICATION; CHOLANGIOCYTE; CHOLESTASIS; COLON; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; DETOXIFICATION; DRUG INHIBITION; EPITHELIUM CELL; GALLSTONE; HEPATOBILIARY SYSTEM; HOMEOSTASIS; HUMAN; INTESTINE; LIVER; LIVER CELL; LIVER CIRCULATION; MOLECULAR BIOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; BILE ACIDS AND SALTS; CARRIER PROTEINS; CHOLESTASIS; HUMANS; LIVER; LIVER DISEASES; LIVER REGENERATION; MEMBRANE GLYCOPROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84871242500     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.08.002     Document Type: Review

References (159)

1. A.F. Hofmann The enterohepatic circulation of bile acids in mammals: form and functions Front Biosci 14 2009 2584 2598
2. A.F. Hofmann Biliary secretion and excretion in health and disease: current concepts Ann Hepatol 6 2007 15 27
3. D.W. Russell Fifty years of advances in bile acid synthesis and metabolism J Lipid Res 50 2009 S120 125
4. M. Trauner, and J.L. Boyer Bile salt transporters: molecular characterization, function, and regulation Physiol Rev 83 2003 633 671
5. 2+ mechanisms defective in cholestasis J Clin Invest 92 1993 2984 2993
6. 2+ signals in isolated rat hepatocytes Gastroenterology 104 1993 604 612
7. U. Beuers, M. Bilzer, A. Chittattu, G.A. Kullak-Ublick, D. Keppler, and G. Paumgartner Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver Hepatology 33 2001 1206 1216
8. F. Schliess, A.K. Kurz, S. Vom Dahl, and D. Haussinger Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver Gastroenterology 113 1997 1306 1314
9. C.D. Klaassen, and L.M. Aleksunes Xenobiotic, bile acid, and cholesterol transporters: function and regulation Pharmacol Rev 62 2010 1 96
10. T. Maruyama, Y. Miyamoto, T. Nakamura, Y. Tamai, H. Okada, and E. Sugiyama Identification of membrane-type receptor for bile acids (M-BAR) Biochem Biophys Res Commun 298 2002 714 719
11. Y.P. Rao, E.J. Studer, R.T. Stravitz, S. Gupta, L. Qiao, and P. Dent Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes Hepatology 35 2002 307 314
12. G.A. Kullak-Ublick, B. Stieger, and P.J. Meier Enterohepatic bile salt transporters in normal physiology and liver disease Gastroenterology 126 2004 322 342
13. +/bile acid cotransporter J Clin Invest 93 1994 1326 1331
14. G.A. Kullak-Ublick, B. Hagenbuch, B. Stieger, A.W. Wolkoff, and P.J. Meier Functional characterization of the basolateral rat liver organic anion transporting polypeptide Hepatology 20 1994 411 416
15. M. Wagner, G. Zollner, and M. Trauner Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis Semin Liver Dis 30 2010 160 177
16. G. Zollner, P. Fickert, D. Silbert, A. Fuchsbichler, H.U. Marschall, and K. Zatloukal Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis J Hepatol 38 2003 717 727
17. V. Keitel, M. Burdelski, U. Warskulat, T. Kuhlkamp, D. Keppler, and D. Haussinger Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis Hepatology 41 2005 1160 1172
18. G. Zollner, H.U. Marschall, M. Wagner, and M. Trauner Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations Mol Pharm 3 2006 231 251
19. T. Gerloff, B. Stieger, B. Hagenbuch, J. Madon, L. Landmann, and J. Roth The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver J Biol Chem 273 1998 10046 10050
20. M. Makishima, A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, and A. Luk Identification of a nuclear receptor for bile acids Science 284 1999 1362 1365
21. B. Stieger The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation Handb Exp Pharmacol 2011 205 259
22. G. Lo Sasso, M. Petruzzelli, and A. Moschetta A translational view on the biliary lipid secretory network Biochim Biophys Acta 1781 2008 79 96
23. I. Cascorbi P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations Handb Exp Pharmacol 2011 261 283
24. H.E. Meyer zu Schwabedissen, and H.K. Kroemer In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2) Handb Exp Pharmacol 2 2011 325 371
25. P.A. Dawson, T. Lan, and A. Rao Bile acid transporters J Lipid Res 50 2009 2340 2357
26. A.F. Hofmann Bile acids: trying to understand their chemistry and biology with the hope of helping patients Hepatology 49 2009 1403 1418
27. -/- mice Hepatology 49 2009 1972 1981
28. T. Claudel, G. Zollner, M. Wagner, and M. Trauner Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease Biochim Biophys Acta 1812 2011 867 878
29. B.L. Shneider Intestinal bile acid transport: biology, physiology, and pathophysiology J Pediatr Gastroenterol Nutr 32 2001 407 417
30. P.A. Dawson, J. Haywood, A.L. Craddock, M. Wilson, M. Tietjen, and K. Kluckman Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice J Biol Chem 278 2003 33920 33927
31. T. Inagaki, M. Choi, A. Moschetta, L. Peng, C.L. Cummins, and J.G. McDonald Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis Cell Metab 2 2005 217 225
32. M. Choi, A. Moschetta, A.L. Bookout, L. Peng, M. Umetani, and S.R. Holmstrom Identification of a hormonal basis for gallbladder filling Nat Med 12 2006 1253 1255
33. J. Sinha, F. Chen, T. Miloh, R.C. Burns, Z. Yu, and B.L. Shneider Beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes Am J Physiol Gastrointest Liver Physiol 295 2008 G996 G1003
34. F.G. Schaap, N.A. van der Gaag, D.J. Gouma, and P.L. Jansen High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis Hepatology 49 2009 1228 1235
35. S. Kir, S.A. Beddow, V.T. Samuel, P. Miller, S.F. Previs, and K. Suino-Powell FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis Science 331 2011 1621 1624
36. S.J. Zweers, K.A. Booij, M. Komuta, T. Roskams, D.J. Gouma, and P.L. Jansen The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract Hepatology 55 2012 575 583
37. C. Thomas, A. Gioiello, L. Noriega, A. Strehle, J. Oury, and G. Rizzo TGR5-mediated bile acid sensing controls glucose homeostasis Cell Metab 10 2009 167 177
38. M. Trauner, P.J. Meier, and J.L. Boyer Molecular pathogenesis of cholestasis N Engl J Med 339 1998 1217 1227
39. M. Trauner, M. Wagner, P. Fickert, and G. Zollner Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis J Clin Gastroenterol 39 2005 S111 124
40. A. Geier, P. Fickert, and M. Trauner Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis Nat Clin Pract Gastroenterol Hepatol 3 2006 574 585
41. R. Kubitz, M. Wettstein, U. Warskulat, and D. Haussinger Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone Gastroenterology 116 1999 401 410
42. M. Trauner, M. Arrese, C.J. Soroka, M. Ananthanarayanan, T.A. Koeppel, and S.F. Schlosser The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis Gastroenterology 113 1997 255 264
43. G. Zollner, P. Fickert, R. Zenz, A. Fuchsbichler, C. Stumptner, and L. Kenner Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases Hepatology 33 2001 633 646
44. E. Hinoshita, K. Taguchi, A. Inokuchi, T. Uchiumi, N. Kinukawa, and M. Shimada Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection J Hepatol 35 2001 765 773
45. B.A. Carter, and R.J. Shulman Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis Nat Clin Pract Gastroenterol Hepatol 4 2007 277 287
46. M. Nishimura, M. Yamaguchi, A. Yamauchi, N. Ueda, and S. Naito Role of soybean oil fat emulsion in the prevention of hepatic xenobiotic transporter mRNA up- and down-regulation induced by overdose of fat-free total parenteral nutrition in infant rats Drug Metab Pharmacokinet 20 2005 46 54
47. B.A. Carter, D.R. Prendergast, O.A. Taylor, T.L. Zimmerman, R.V. Furstenberg, and D.D. Moore Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR Pediatr Res 62 2007 301 306
48. M. Nishimura, M. Yamaguchi, S. Naito, and A. Yamauchi Soybean oil fat emulsion to prevent TPN-induced liver damage: possible molecular mechanisms and clinical implications Biol Pharm Bull 29 2006 855 862
49. D. Mesotten, J. Wauters, G. Van den Berghe, P.J. Wouters, I. Milants, and A. Wilmer The effect of strict blood glucose control on biliary sludge and cholestasis in critically ill patients J Clin Endocrinol Metab 94 2009 2345 2352
50. D. Duran-Sandoval, G. Mautino, G. Martin, F. Percevault, O. Barbier, and J.C. Fruchart Glucose regulates the expression of the farnesoid X receptor in liver Diabetes 53 2004 890 898
51. B. Stieger, K. Fattinger, J. Madon, G.A. Kullak-Ublick, and P.J. Meier Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver Gastroenterology 118 2000 422 430
52. Y. Meier, C. Pauli-Magnus, U.M. Zanger, K. Klein, E. Schaeffeler, and A.K. Nussler Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver Hepatology 44 2006 62 74
53. C. Lang, Y. Meier, B. Stieger, U. Beuers, T. Lang, and R. Kerb Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury Pharmacogenet Genomics 17 2007 47 60
54. G. Zollner, M. Wagner, P. Fickert, D. Silbert, J. Gumhold, and K. Zatloukal Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis Liver Int 27 2007 920 929
55. J.L. Boyer, M. Trauner, A. Mennone, C.J. Soroka, S.Y. Cai, and T. Moustafa Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents Am J Physiol Gastrointest Liver Physiol 290 2006 G1124 1130
56. J. Shoda, M. Kano, K. Oda, J. Kamiya, Y. Nimura, and H. Suzuki The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function Am J Gastroenterol 96 2001 3368 3378
57. A. Geier, M. Wagner, C.G. Dietrich, and M. Trauner Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration Biochim Biophys Acta 1773 2007 283 308
58. G. Zollner, and M. Trauner Nuclear receptors as therapeutic targets in cholestatic liver diseases Br J Pharmacol 156 2009 7 27
59. H. Tanaka, and I. Makino Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor Biochem Biophys Res Commun 188 1992 942 948
60. H.U. Marschall, M. Wagner, G. Zollner, P. Fickert, U. Diczfalusy, and J. Gumhold Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans Gastroenterology 129 2005 476 485
61. U. Beuers Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis Nat Clin Pract Gastroenterol Hepatol 3 2006 318 328
62. G. Paumgartner, and U. Beuers Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited Hepatology 36 2002 525 531
63. J.L. Staudinger, B. Goodwin, S.A. Jones, D. Hawkins-Brown, K.I. MacKenzie, and A. LaTour The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity Proc Natl Acad Sci USA 98 2001 3369 3374
64. G. Zollner, P. Fickert, A. Fuchsbichler, D. Silbert, M. Wagner, and S. Arbeiter Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine J Hepatol 39 2003 480 488
65. G. Zollner, M. Wagner, T. Moustafa, P. Fickert, D. Silbert, and J. Gumhold Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids Am J Physiol Gastrointest Liver Physiol 290 2006 G923 932
66. F. Arenas, I. Hervias, M. Uriz, R. Joplin, J. Prieto, and J.F. Medina Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells J Clin Invest 118 2008 695 709
67. J.F. Medina, A. Martinez, J.J. Vazquez, and J. Prieto Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis Hepatology 25 1997 12 17
68. J. Prieto, N. Garcia, J.M. Marti-Climent, I. Penuelas, J.A. Richter, and J.F. Medina Assessment of biliary bicarbonate secretion in humans by positron emission tomography Gastroenterology 117 1999 167 172
69. J.F. Medina Role of the anion exchanger 2 in the pathogenesis and treatment of primary biliary cirrhosis Dig Dis 29 2011 103 112
70. J.T. Salas, J.M. Banales, S. Sarvide, S. Recalde, A. Ferrer, and I. Uriarte Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis Gastroenterology 134 2008 1482 1493
71. H. Rautiainen, P. Karkkainen, A.L. Karvonen, H. Nurmi, P. Pikkarainen, and H. Nuutinen Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial Hepatology 41 2005 747 752
72. Mason A, Luketic V, Lindor K, Hirschfield G, Gordon S, Mayo M, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of int-747 to ursodeoxycholic acid. EASL 2010. Available from: http://www.kenes.com/easl2010/orals/105.htm.
73. M. Wagner, G. Zollner, and M. Trauner Nuclear receptors in liver disease Hepatology 53 2011 1023 1034
74. L. Huang, A. Zhao, J.L. Lew, T. Zhang, Y. Hrywna, and J.R. Thompson Farnesoid X-receptor activates transcription of the phospholipid pump MDR3 J Biol Chem 278 2003 51085 51090
75. J. Shoda, Y. Inada, A. Tsuji, H. Kusama, T. Ueda, and T. Ikegami Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4 J Lipid Res 45 2004 1813 1825
76. R. Hazzan, and R. Tur-Kaspa Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid J Clin Gastroenterol 44 2010 371 373
77. EASL Clinical Practice Guidelines Management of cholestatic liver diseases J Hepatol 51 2009 237 267
78. M. Nakamuta, T. Fujino, R. Yada, K. Yasutake, T. Yoshimoto, and N. Harada Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway Int J Clin Pharmacol Ther 48 2010 22 28
79. A. Baghdasaryan, T. Claudel, J. Gumhold, D. Silbert, L. Adorini, and A. Roda Dual FXR/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO3- output Hepatology 54 2011 1303 1312
80. P. Fickert, M. Wagner, H.U. Marschall, A. Fuchsbichler, G. Zollner, and O. Tsybrovskyy 24-norursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice Gastroenterology 130 2006 465 481
81. Y.B. Yoon, L.R. Hagey, A.F. Hofmann, D. Gurantz, E.L. Michelotti, and J.H. Steinbach Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents Gastroenterology 90 1986 837 852
82. T. Moustafa, P. Fickert, C. Magnes, C. Guelly, A. Thueringer, and S. Frank Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury Gastroenterology 142 140-151 2012 e112
83. L. Bachs, A. Pares, M. Elena, C. Piera, and J. Rodes Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis Lancet 1 1989 574 576
84. W. Huang, J. Zhang, and D.D. Moore A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR J Clin Invest 113 2004 137 143
85. M. Wagner, E. Halilbasic, H.U. Marschall, G. Zollner, P. Fickert, and C. Langner CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice Hepatology 42 2005 420 430
86. K.J. Van Erpecum Pathogenesis of cholesterol and pigment gallstones: an update Clin Res Hepatol Gastroenterol 35 2011 281 287
87. H. Wittenburg, M.A. Lyons, R. Li, G.A. Churchill, M.C. Carey, and B. Paigen FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice Gastroenterology 125 2003 868 881
88. M. Krawczyk, D.Q. Wang, P. Portincasa, and F. Lammert Dissecting the genetic heterogeneity of gallbladder stone formation Semin Liver Dis 31 2011 157 172
89. Z.Y. Jiang, P. Parini, G. Eggertsen, M.A. Davis, H. Hu, and G.J. Suo Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients J Lipid Res 49 2008 464 472
90. H. Uppal, Y. Zhai, A. Gangopadhyay, S. Khadem, S. Ren, and J.A. Moser Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization Hepatology 47 2008 1331 1342
91. S.B. Biddinger, J.T. Haas, B.B. Yu, O. Bezy, E. Jing, and W. Zhang Hepatic insulin resistance directly promotes formation of cholesterol gallstones Nat Med 14 2008 778 782
92. A. Henkel, Z. Wei, D.E. Cohen, and R.M. Green Mice overexpressing hepatic Abcb11 rapidly develop cholesterol gallstones Mamm Genome 16 2005 903 908
93. -/- mice. a model for low phospholipid-associated cholelithiasis Hepatology 39 2004 117 128
94. O. Rosmorduc, and R. Poupon Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene Orphanet J Rare Dis 2 2007 29
95. M. Acalovschi, S. Tirziu, E. Chiorean, M. Krawczyk, F. Grunhage, and F. Lammert Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls Lipids 44 2009 521 526
96. A. Moschetta, A.L. Bookout, and D.J. Mangelsdorf Prevention of cholesterol gallstone disease by FXR agonists in a mouse model Nat Med 10 2004 1352 1358
97. P. Kovacs, R. Kress, J. Rocha, U. Kurtz, J.F. Miquel, and F. Nervi Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans J Hepatol 48 2008 116 124
98. I. Bergheim, S. Harsch, O. Mueller, S. Schimmel, P. Fritz, and E.F. Stange Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers J Lipid Res 47 2006 42 50
99. O. Renner, S. Harsch, E. Schaeffeler, S. Winter, M. Schwab, and M. Krawczyk A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease PLoS ONE 4 2009 e7321
100. D. Jung, A.C. Fantin, U. Scheurer, M. Fried, and G.A. Kullak-Ublick Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor Gut 53 2004 78 84
101. W. Wang, S. Xue, S.A. Ingles, Q. Chen, A.T. Diep, and H.D. Frankl An association between genetic polymorphisms in the ileal sodium-dependent bile acid transporter gene and the risk of colorectal adenomas Cancer Epidemiol Biomarkers Prev 10 2001 931 936
102. F. Grunhage, M. Jungck, C. Lamberti, H. Keppeler, U. Becker, and H. Schulte-Witte Effects of common haplotypes of the ileal sodium dependent bile acid transporter gene on the development of sporadic and familial colorectal cancer: a case control study BMC Med Genet 9 2008 70
103. T. Inagaki, A. Moschetta, Y.K. Lee, L. Peng, G. Zhao, and M. Downes Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor Proc Natl Acad Sci USA 103 2006 3920 3925
104. R.M. Gadaleta, K.J. van Erpecum, B. Oldenburg, E.C. Willemsen, W. Renooij, and S. Murzilli Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease Gut 60 2011 463 472
105. S. Modica, M. Petruzzelli, E. Bellafante, S. Murzilli, L. Salvatore, and N. Celli Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis Gastroenterology 142 2012 355 365 e1-4
106. A.E. Kremer, R.V. Dijk, P. Leckie, F.G. Schaap, E.M. Kuiper, and T. Mettang Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions Hepatology 56 2012 1391 1400
107. A. Garg, and S.M. Grundy Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial Ann Intern Med 121 1994 416 422
108. Q. Shang, M. Saumoy, J.J. Holst, G.E. Salen, and G. Xu Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1 Am J Physiol Gastrointest Liver Physiol 298 2010 G419 G424
109. J. Shepherd, C.J. Packard, H.G. Morgan, J.L. Third, J.M. Stewart, and T.D. Lawrie The effects of cholestyramine on high density lipoprotein metabolism Atherosclerosis 33 1979 433 444
110. H. Buchwald, R.L. Varco, J.P. Matts, J.M. Long, L.L. Fitch, and G.S. Campbell Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the program on the surgical control of the hyperlipidemias (POSCH) N Engl J Med 323 1990 946 955
111. M.W. Huff, D.E. Telford, J.Y. Edwards, J.R. Burnett, P.H. Barrett, and S.R. Rapp Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB Arterioscler Thromb Vasc Biol 22 2002 1884 1891
112. -/- mice by SC-435 J Lipid Res 44 2003 1614 1621
113. M. Simren, A. Bajor, P.G. Gillberg, M. Rudling, and H. Abrahamsson Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study Aliment Pharmacol Ther 34 2011 41 50
114. - secretion induced by taurodeoxycholate from colon mucosa Biol Cell 95 2003 115 122
115. A.F. Hofmann, V. Loening-Baucke, J.E. Lavine, L.R. Hagey, J.H. Steinbach, and C.A. Packard Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients J Pediatr Gastroenterol Nutr 47 2008 598 606
116. A.S. Rao, B.S. Wong, M. Camilleri, S.T. Odunsi-Shiyanbade, S. McKinzie, and M. Ryks Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis Gastroenterology 139 2010 1549-1558, e1541
117. F. Fernandez-Banares, M. Esteve, A. Salas, M. Alsina, C. Farre, and C. Gonzalez Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics Am J Gastroenterol 102 2007 2520 2528
118. L. Sinha, R. Liston, H.J. Testa, and K.J. Moriarty Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine Aliment Pharmacol Ther 12 1998 839 844
119. P.B. Hylemon, H. Zhou, W.M. Pandak, S. Ren, G. Gil, and P. Dent Bile acids as regulatory molecules J Lipid Res 50 2009 1509 1520
120. C. Thomas, R. Pellicciari, M. Pruzanski, J. Auwerx, and K. Schoonjans Targeting bile-acid signalling for metabolic diseases Nat Rev Drug Discov 7 2008 678 693
121. A. Figge, F. Lammert, B. Paigen, A. Henkel, S. Matern, and R. Korstanje Hepatic over-expression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis J Biol Chem 279 2004 2790 2799
122. S.S. Sundaram, P.F. Whitington, and R.M. Green Steatohepatitis develops rapidly in transgenic mice overexpressing Abcb11 and fed a methionine-choline- deficient diet Am J Physiol Gastrointest Liver Physiol 288 2005 G1321 1327
123. G. Andreotti, I. Menashe, J. Chen, S.C. Chang, A. Rashid, and Y.T. Gao Genetic determinants of serum lipid levels in Chinese subjects: a population-based study in Shanghai, China Eur J Epidemiol 24 2009 763 774
124. M. Krawczyk, M. Rusticeanu, and Fea Grunhage Body mass index in the general population is associated with the common p.A444V variant of the ABC transporter for bile salts Hepatology 50 2009 1016A
125. M. Pizarro, N. Balasubramaniyan, N. Solis, A. Solar, I. Duarte, and J.F. Miquel Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function Gut 53 2004 1837 1843
126. A.R. Chopra, R. Kommagani, P. Saha, J.F. Louet, C. Salazar, and J. Song Cellular energy depletion resets whole-body energy by promoting coactivator-mediated dietary fuel absorption Cell Metab 13 2011 35 43
127. Q. Cheng, L.M. Aleksunes, J.E. Manautou, N.J. Cherrington, G.L. Scheffer, and H. Yamasaki Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity Mol Pharm 5 2008 77 91
128. P. Fickert, G. Zollner, A. Fuchsbichler, C. Stumptner, C. Pojer, and R. Zenz Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver Gastroenterology 121 2001 170 183
129. M. Haedrich, and J.F. Dufour UDCA for NASH: end of the story? J Hepatol 54 2011 856 858
130. U. Ozcan, E. Yilmaz, L. Ozcan, M. Furuhashi, E. Vaillancourt, and R.O. Smith Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes Science 313 2006 1137 1140
131. J.S. Yang, J.T. Kim, J. Jeon, H.S. Park, G.H. Kang, and K.S. Park Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice PLoS One 5 2010 e13858
132. V. Ratziu, V. de Ledinghen, F. Oberti, P. Mathurin, C. Wartelle-Bladou, and C. Renou A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis J Hepatol 54 2011 1011 1019
133. A. Sanyal, S. Mudaliar, R.R. Henry, H.U. Marschall, L. Morrow, and C.I. Sciacca A new therapy for nnonalcoholic fatty liver disease and diabetes? INT-747 - the first FXR hepatic therapeutic study Hepatology 50 2009 302A
134. S. Zhang, J. Wang, Q. Liu, and D.C. Harnish Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis J Hepatol 51 2009 380 388
135. N.A. Gupta, J. Mells, R.M. Dunham, A. Grakoui, J. Handy, and N.K. Saxena Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway Hepatology 51 2010 1584 1592
136. G. Svegliati-Baroni, S. Saccomanno, C. Rychlicki, L. Agostinelli, S. De Minicis, and C. Candelaresi Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 31 2011 1285 1297
137. X. Ding, N.K. Saxena, S. Lin, N.A. Gupta, and F.A. Anania Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 43 2006 173 181
138. H.S. Xu, L.K. Rosenlof, and R.S. Jones Bile secretion and liver regeneration in partially hepatectomized rats Ann Surg 218 1993 176 182
139. T. Miura, N. Kimura, T. Yamada, T. Shimizu, N. Nanashima, and D. Yamana Sustained repression and translocation of Ntcp and expression of Mrp4 for cholestasis after rat 90% partial hepatectomy J Hepatol 55 2011 407 414
140. T. Gerloff, A. Geier, B. Stieger, B. Hagenbuch, P.J. Meier, and S. Matern Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver Gastroenterology 117 1999 1408 1415
141. T.A. Vos, J.E. Ros, R. Havinga, H. Moshage, F. Kuipers, and P.L. Jansen Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats Hepatology 29 1999 1833 1839
142. T.H. Chang, K. Hakamada, Y. Toyoki, S. Tsuchida, and M. Sasaki Expression of MRP2 and MRP3 during liver regeneration after 90% partial hepatectomy in rats Transplantation 77 2004 22 27
143. A. Geier, C.G. Dietrich, S. Voigt, S.K. Kim, T. Gerloff, and G.A. Kullak-Ublick Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis Hepatology 38 2003 345 354
144. G. Fernández-Barrena Maite, J. Monte Maria, U. Latasa Maria, I. Uriarte, Eva Vicente, and Cy Chang Haisul Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice J Hepatol 56 2012 367 373
145. J. Ueda, K. Chijiiwa, K. Nakano, G. Zhao, and M. Tanaka Lack of intestinal bile results in delayed liver regeneration of normal rat liver after hepatectomy accompanied by impaired cyclin E-associated kinase activity Surgery 131 2002 564 573
146. M. Barone, A. Francavilla, L. Polimeno, E. Ierardi, D. Romanelli, and P. Berloco Modulation of rat hepatocyte proliferation by bile salts: in vitro and in vivo studies Hepatology 23 1996 1159 1166
147. L. Chen, J. McNulty, D. Anderson, Y. Liu, C. Nystrom, and S. Bullard Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats J Pharmacol Exp Ther 334 2010 164 170
148. W. Huang, K. Ma, J. Zhang, M. Qatanani, J. Cuvillier, and J. Liu Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration Science 312 2006 233 236
149. L. Zhang, X. Huang, Z. Meng, B. Dong, S. Shiah, and D.D. Moore Significance and mechanism of CYP7a1 gene regulation during the acute phase of liver regeneration Mol Endocrinol 23 2009 137 145
150. Zhang L, Wang YD, Chen WD, Wang X, Lou G, Liu N, et al. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine. Hepatology 2012. in press, http://dx.doi.org/10.1002/hep.25905.
151. A. Milona, B.M. Owen, S. van Mil, D. Dormann, C. Mataki, and M. Boudjelal The normal mechanisms of pregnancy-induced liver growth are not maintained in mice lacking the bile acid sensor Fxr Am J Physiol Gastrointest Liver Physiol 298 2010 G151 G158
152. T.H. Mauad, C.M. van Nieuwkerk, K.P. Dingemans, J.J. Smit, A.H. Schinkel, and R.G. Notenboom Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis Am J Pathol 145 1994 1237 1245
153. F. Yang, X. Huang, T. Yi, Y. Yen, D.D. Moore, and W. Huang Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor Cancer Res 67 2007 863 867
154. A. Wolfe, A. Thomas, G. Edwards, R. Jaseja, G.L. Guo, and U. Apte Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice J Pharmacol Exp Ther 338 2011 12 21
155. S. Lax, G. Schauer, K. Prein, M. Kapitan, D. Silbert, and A. Berghold Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis Int J Cancer 130 2012 2232 2239
156. A.O. Scheimann, S.S. Strautnieks, A.S. Knisely, J.A. Byrne, R.J. Thompson, and M.J. Finegold Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma J Pediatr 150 2007 556 559
157. V. Keitel, R. Reinehr, M. Reich, A. Sommerfeld, K. Cupisti, and W.T.
158. G. Zollner, M. Wagner, P. Fickert, D. Silbert, A. Fuchsbichler, and K. Zatloukal Hepatobiliary transporter expression in human hepatocellular carcinoma Liver Int 25 2005 367 379
159. T. Tsuboyama, H. Onishi, T. Kim, H. Akita, M. Hori, and M. Tatsumi Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation Radiology 255 2010 824 833